ANTI DIABETES CAMPAIGN : Diabetic Must Take Extra GTF

BACKGROUND
Diabetes is recognized as a major global health problem. Diabetes affects 5%-10% of the population in developed countries, while in developing countries the disease has been recently declared an "epidemic". Diabetics suffer from lack of insulin or a deficiency in the body's ability to respond to insulin. Diabetes is a chronic illness with no cure and can lead to kidney failure, heart problems, strokes or blindness, as well as other complications. Approximately 50% of diabetics are treated with insulin, which has to be injected, while the rest are treated with oral medications which tend to be more difficult to regulate and often have side effects.

RESEARCH AND FINDING
According to Dr. Mirsky, there are a number of problems with insulin treatment; the main one being that insulin is not always an effective treatment, due to gradual development of resistance to the hormone. An additional problem is that insulin doses are not necessarily synchronized with the patient's physical activities or eating intervals. A large dose of insulin injected before a diabetic patient eats, for example, can cause a sudden drop in blood sugar (hypoglycemia) that can result in a diabetic coma and ultimately death. In addition, the fact that insulin must be injected is in and of itself difficult for many patients.

Research in the Department of Biology at the Faculty of Science and Science Education of the University of Haifa has discovered a substance that may become an oral treatment for diabetes and its complications. The substance is called Glucose Tolerance Factor (GTF). "The research is now at the stage where the substance has been successfully tested on diabetic rats and was found to reduce sugar and lipids in the blood of the treated animals. The next stage of the research is to evaluate GTF efficacy in humans," said Dr. Nitsa Mirsky, who is conducting the research.

STABLE GTF SUBSTANCE
Maxluck Biotechnology Corp. have studied colostrums GTF for many years, we finally had a remarkable breakthrough and successfully manufactured colostrums GTF (brand name GT&F®). The GT&F® technology is a patented technology (USP 6,379,693) approved by USPTO. This biotechnological technique can mass produce GT&F®, instead of extracting colostrums GTF. GT&F® is made by blending GT&F® with New Zealand best grade milk powder to mimic the bioactivity of colostrums GTF.

Since GT&F® is non-toxic, does not produce side effects, contains no drugs, hormones, or toxins, it is safe to take. GT&F® is able to effectively promote functioning of insulin, and long-term use provides body with sufficient GTF to maintain homeostasis of blood sugar and also will prevent the occurrence of type 2 diabetes and its complications.

GT&F Clinical Test Results: Published in The 25 th Annual Meeting of The Endocrinology Society and The Diabetes Association of The R.O.C. 2004

Chromium supplement offers diabetes hope

DIABETIC STATISTICS
An estimated 19 million people are affected by diabetes in the EU, equal to four per cent of the total population. This figure is projected to increase to 26 million by 2030.

In the US, there are over 20 million people with diabetes, equal to seven per cent of the population. The total costs are thought to be as much as $132 billion, with $92 billion being direct costs from medication, according to 2002 American Diabetes Association figures.

CHROMIUM REQUIREMENT
Researchers have reported how chromium (one of the component in GTF) improves muscle sensitivity to insulin in obese, insulin-resistant rats - findings that could have implications for diabetic humans.
Insulin resistance occurs when muscle and fat tissue, for example, react poorly to insulin, the hormone responsible for glucose metabolism. The condition is found in both pre-diabetics and those with fully developed diabetes.

Previous research has shown that chromium supplements could enhance insulin sensitivity by improving receptor signalling, but these had been limited to in vitro studies.

The new study, published in the Journal of Nutrition (Vol 136, pp. 415-420), is the first to use in vivo animal models to demonstrate the mechanism.

Also, The Clinical Test has been published in Journal Metabolism Clinical & Experimental Vol. 55 (2006) Pg. 923-927

Title: The influence of chromium chloride–containing milk to glycemic control of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial.

~END